ResMed Reports 11% Revenue Growth to $1.43 Billion for Quarter Ended March 31, 2026

ResMed Inc. reported a strong financial performance for the three months ended March 31, 2026, with net revenue reaching $1.43 billion, an increase of 11% compared to $1.29 billion in the same period last year. The company's gross profit also rose to $891 million, reflecting a gross margin of 62.2%, up from 59.3% a year earlier. Net income for the quarter was $398.7 million, translating to diluted earnings per share of $2.74, compared to $365 million and $2.48 per share in the prior year. For the nine months ended March 31, 2026, net revenue totaled $4.19 billion, a 10% increase from $3.80 billion, with net income of $1.14 billion, up 12% from $1.02 billion.

The company experienced notable growth in its Sleep and Breathing Health segment, which generated $1.26 billion in revenue for the quarter, marking an 11% increase year-over-year. This growth was driven by increased demand and unit sales of devices and masks. The Residential Care Software segment also contributed positively, with revenues rising 6% to $170.9 million. ResMed's cash and cash equivalents stood at $1.66 billion as of March 31, 2026, up from $1.21 billion a year earlier, indicating a solid liquidity position.

In terms of operational developments, ResMed's employee headcount and customer engagement metrics have shown positive trends. The company continues to invest in research and development, allocating $94.3 million in the latest quarter, which represents 6.6% of net revenues. This investment supports the development of innovative products, including the recently launched AirSense 11 device, which features advanced technology aimed at improving patient outcomes. The company also reported a significant increase in its treasury stock repurchases, totaling $500 million during the nine months ended March 31, 2026, compared to $200 million in the same period last year.

Looking ahead, ResMed remains optimistic about its growth trajectory, driven by ongoing product innovation and geographic expansion. The company is focused on enhancing its digital health solutions and expanding its market presence in both existing and new regions. Management anticipates that the continued demand for respiratory health solutions will support revenue growth, despite potential challenges from macroeconomic conditions and competitive pressures. The company is also closely monitoring regulatory developments and their potential impact on its operations and financial performance.